LILLY ENDOWMENT INC, an insider at Eli Lilly and Co (LLY), executed a significant transaction on November 10, 2025, selling 93,683,290 shares of the company’s stock at a price of $972.27 per share. This sale amounted to a total value of $91,085.36 million.
Following this transaction, LILLY ENDOWMENT INC retains 93,683,290 shares in Eli Lilly. The move underscores the complexities of insider trading, which can occur for various reasons such as diversification, tax planning, or personal financial needs. While substantial selling activity may attract attention, it does not inherently signal negative sentiment toward the company.
Eli Lilly, a leading player in the pharmaceuticals industry, focuses on the discovery, development, manufacture, and sale of medicinal products. The company, headquartered in Indianapolis, Indiana, employs approximately 47,000 full-time staff. Its diverse portfolio includes cardiometabolic health products like Humalog and Jardiance, oncology treatments such as Cyramza and Verzenio, and immunology products including Taltz and Olumiant.
As of November 13, 2025, Eli Lilly's market capitalization stands at $962.2 billion, with a P/E ratio of 52.26 and an EPS of 20.45. The company is scheduled to report its next earnings on April 28, 2026, with an estimated EPS of $7.07 and projected revenue of $17.2 billion.
Investors are advised to consider insider transactions as part of a broader analysis, examining patterns across multiple insiders and timeframes rather than isolated events.